AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28235537
Drug: R3 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R3 group (3ng/ml of remifentanil)
Trial: 27923389
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion of 5% albumin (180 minutes) at a dose of 10 ml/kg ideal body weight
Trial: 27923389
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion of 5% albumin (30 minutes) at a dose of 10 ml/kg ideal body weight
Trial: 27923389
Drug: Both rapid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both rapid and slow infusion of 5% albumin
Trial: 22374642
Drug: Separate injection
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate injection of aspart and detemir
Trial: 22374642
Drug: Mixed injection
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed injection of aspart and detemir
Trial: 19319701
Drug: Prophylactic antiepileptic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antiepileptic drugs (AEDs) initiated in 23 patients (8%) without documented seizure during the first 10 days of the trial.
Trial: 17000884
Drug: Enoxaparin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily for 175 days
Trial: 17000884
Drug: Enoxaparin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1.0 mg/kg every 12 hours for at least 5 days followed by warfarin (stable INR of 2 to 3)
Trial: 12491503
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m(2)) followed by paclitaxel (175 mg/m(2) 3‐hour infusion; AT)
Trial: 12491503
Drug: Doxorubicin-cyclophosphamide regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-cyclophosphamide regimen (AC; 60/600 mg/m(2))
Trial: 10664499
Drug: HBOC (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC (60 g for initial transfusion, with options for three more doses of 30 g each within 96 hours)
Trial: 6238910
Drug: Chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (25 mg/day)
Trial: 6238910
Drug: Severe restriction
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe restriction of salt intake (about 1016 mg Na+/day)
Trial: 6238910
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified, but implied to be no treatment during initial 2 weeks)
Trial: 22285545
Drug: DepoFoam bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoFoam bupivacaine 133 mg
Trial: 22285545
Drug: DepoFoam bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoFoam bupivacaine 266 mg
Trial: 22285545
Drug: DepoFoam bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoFoam bupivacaine 399 mg
Trial: 22285545
Drug: DepoFoam bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoFoam bupivacaine 532 mg
Trial: 22285545
Drug: bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine HCl 150 mg
Trial: 20385935
Drug: Lutein 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein 12 mg daily plus vitamin A 15,000 IU/d
Trial: 20385935
Drug: Control tablet
RxNorm normalized name: Daily-Vite Weight Control Tablet
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control tablet plus vitamin A 15,000 IU/d
Trial: 16214917
Drug: Low-fat, high-fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-fiber diet (18 g/1,000 kcal, 3.5 servings of fruits and vegetables/1,000 kcal, 20% energy)
Trial: 24471477
Drug: FSK0808 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSK0808 (200 µg/m² intravenous dose)
Trial: 24471477
Drug: Gran® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gran® (200 µg/m² intravenous dose)
Trial: 24471477
Drug: FSK0808 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSK0808 (400 µg/m² subcutaneous dose)
Trial: 24471477
Drug: Gran® (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gran® (400 µg/m² subcutaneous dose)
Trial: 12975689
Drug: Acamprosate (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (six tablets of 333 mg/d for 12 weeks)
Trial: 12975689
Drug: Placebo (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (six tablets for 12 weeks)
Trial: 1394816
Drug: Adriamycin (ADM)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADM) intravesical instillation therapy
Trial: 29549007
Drug: Rate Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate Reduction (including nicotine replacement therapy in the form of gum)
Trial: 26811156
Drug: UGT1A1 genotyping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGT1A1 genotyping with irinotecan dose escalation
Trial: 17478952
Drug: Continuous pump
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous pump infusion of 0.75% ropivacaine (12 mL initial dose, 6 mL/hour thereafter) in Group A
Trial: 17478952
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection of 0.75% ropivacaine (15 mL initial dose, 6 mL injected 80 min later) in Group B
Trial: 16235667
Drug: GCF-glucose monitor;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCF-glucose monitor; specific dosage and duration not mentioned.
Trial: 12117087
Drug: 0.5% fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% fluorouracil cream (once daily)
Trial: 12117087
Drug: 5% fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% fluorouracil cream (twice daily)
Trial: 11374329
Drug: Treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimen (capsule each night, as needed, or every third night)
Trial: 9757979
Drug: Histamine blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine blockers (Disease-paired Control)
Trial: 3144198
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen flow at 0 L/min
Trial: 3144198
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen flow at 2 L/min
Trial: 3144198
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen flow at 4 L/min
Trial: 3144198
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine application
Trial: 10922429
Drug: Simvastatin therapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin therapy (starting at 20 mg/day, titrated to 40 mg/day if cholesterol >5.2 mmol/L)
Trial: 26003436
Drug: Telehealth behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth behavioral treatment (TBT)
Trial: 20877714
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (AL) treatment for fever in the intervention group
Trial: 20877714
Drug: Early and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early and appropriate treatment with amoxicillin for nonsevere pneumonia in the intervention group
Trial: 20877714
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment for fever
Trial: 20877714
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment for nonsevere pneumonia
Trial: 19927606
Drug: Ferrous glycine
RxNorm normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous glycine phosphate and riboflavin added to school meals (28 mg of elemental iron and 1 mg of riboflavin per child per day) for 6 months.
Trial: 16306925
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (10 mg daily for 6 months)
Trial: 16306925
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg daily for 6 months)
Trial: 16306925
Drug: Combined iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined iron and zinc supplementation (10 mg iron + 10 mg zinc daily for 6 months)
Trial: 11426091
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 mg/kg) with 1% lidocaine infiltration
Trial: 11426091
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 mg/kg) with normal saline infiltration
Trial: 27803392
Drug: 3K3A-APC (study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3K3A-APC (study drug), dosage not specified, used in conjunction with intra-arterial therapy (IAT)
Trial: 22407197
Drug: Low-dose penicillin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose penicillin G
Trial: 22407197
Drug: High-dose penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose penicillin G
Trial: 22889883
Drug: Sequential radial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radial artery grafts (Group A)
Trial: 8763594
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg 12-hourly for 8 days
Trial: 8763594
Drug: Amoxicillin-clavulanate 500
RxNorm normalized name: amoxicillin-clavulanate 500 mg-125 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate 500 mg 8-hourly for 8 days
Trial: 1678033
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 4000 U calcium heparin over 4 hours
Trial: 1678033
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 12,500 U calcium heparin
Trial: 6953729
Drug: Epidural pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural pethidine (20 or 60 mg)
Trial: 6953729
Drug: Parenteral pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral pethidine (2 mg/kg body weight intramuscularly)
Trial: 23374328
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (400 mg/day)
Trial: 10611184
Drug: 150 IU
RxNorm normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon)
Trial: 10611184
Drug: 250 IU
RxNorm normalized name: Calcium/Vitamin D 250 MG-250 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon)
Trial: 10611184
Drug: 250 IU
RxNorm normalized name: Calcium/Vitamin D 250 MG-250 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon) in 30-33 age class
Trial: 10611184
Drug: 150 IU
RxNorm normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon) in 37-39 age class
Trial: 24799585
Drug: Providing full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Providing full drug coverage for nonwhite patients
Trial: 24799585
Drug: Providing full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Providing full drug coverage for white patients
Trial: 22672221
Drug: Improved glycemic
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved glycemic control (cholesterol decreased by 17% to 4.3 ± 1.3 mmol/L)
Trial: 20199979
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 plus carboplatin AUC 6
Trial: 20199979
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 plus oxaliplatin 120 mg/m2
Trial: 20199979
Drug: Pemetrexed treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed treatment
Trial: 16081445
Drug: Daily multivitamin
RxNorm normalized name: DAILY MULTIVITAMIN TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin and multimineral supplementation
Trial: 8681492
Drug: Captopril, 25
RxNorm normalized name: Captopril, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 25 mg three times a day for 7 days
Trial: 24297763
Drug: Robotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic therapy (12 hours)
Trial: 24297763
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (12 hours)
Trial: 19192016
Drug: Cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing 6.0% Stryphnodendron adstringens bark extract
Trial: 16002033
Drug: Daily IVR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily IVR monitoring for 28 days
Trial: 16002033
Drug: Weekly IVR
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IVR monitoring for 4 weeks
Trial: 7917196
Drug: Prednisone therapy
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone therapy taper from 60 mg orally decreasing by 10 mg each day over 6 days
Trial: 2490831
Drug: Increased treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased treatment of hypertension (antihypertensive medication)
Trial: 2490831
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment of hypertension
Trial: 2490831
Drug: Factors other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors other than antihypertensive treatment
Trial: 7001039
Drug: Chloroquine prophylaxis
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine prophylaxis administered at intervals of 3 months
Trial: 30037726
Drug: ACR of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACR of 30 to 299 mg/g
Trial: 30037726
Drug: ACR ≥
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACR ≥ 300 mg/g
Trial: 19352063
Drug: BCAA drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA drink (0.4% BCAA, 4% carbohydrate; 1,500 mL/d)
Trial: 8873503
Drug: Alendronate 40
RxNorm normalized name: ALENDRONATE 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 40 mg/day
Trial: 9110064
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (500 mg six times daily)
Trial: 9110064
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (5 mg/kg once daily)
Trial: 1748537
Drug: Liquid prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid prepared from effervescent IP tablets
Trial: 27578231
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron 4mg in 10mL of saline
Trial: 23378709
Drug: Low-fluence Q-switched
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fluence Q-switched Nd: YAG laser (QSNYL) at weekly intervals
Trial: 23378709
Drug: Topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20% azelaic acid cream applied twice daily
Trial: 23378709
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-fluence QSNYL and topical 20% azelaic acid cream
Trial: 20529547
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose potassium sodium hydrogen citrate (1 g/d)
Trial: 20529547
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose potassium sodium hydrogen citrate (2 g/d)
Trial: 20529547
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of PSHC (1 g/d and 2 g/d)
Trial: 12486491
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) 800 mg infusion
Trial: 28254171
Drug: Weekly food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly food provision reflecting this advice (n = 148)
Trial: 21075681
Drug: Cyproheptadine hydrochloride
RxNorm normalized name: Cyproheptadine Hydrochloride
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyproheptadine hydrochloride (serotonin receptor 5-HT2 antagonist)
Trial: 19548855
Drug: Sustained-release fampridine
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release fampridine (fampridine SR)
Trial: 17095643
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g bovine colostrum protein concentrate (CPC)/day
Trial: 14507547
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy for bulimia nervosa
Trial: 11054194
Drug: Glucagon 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon 0.03 mg/kg
Trial: 1443818
Drug: 2 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg.kg‐1 of ketamine
Trial: 1443818
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml of normal saline)
Trial: 31657615
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement containing two genera and five species of bacteria
Trial: 28278361
Drug: Individualised nurse-led
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualised nurse-led home exercise prescription and behavioural support for 12 weeks
Trial: 28278361
Drug: In-centre group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-centre group exercise training weekly for 6 weeks
Trial: 25473823
Drug: Intermittent lower-body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent lower-body negative pressure (LBNP) therapy for 60 min daily after exercise
Trial: 25473823
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LBNP therapy)
Trial: 24350408
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 1 g every eight hours (q8h) for 24 hours
Trial: 24350408
Drug: 3-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hour infusion of 1 g q8h for 24 hours
Trial: 24350408
Drug: 3-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hour infusion of 2 g q8h for 24 hours
Trial: 24350408
Drug: 3-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hour infusion regimens
Trial: 19604597
Drug: Extended information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended information regarding new influenza drugs
Trial: 19604597
Drug: Limited information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited information regarding new influenza drugs
Trial: 17245718
Drug: IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN alpha‐2a treatment
Trial: 14982567
Drug: Ropivacaine 2
RxNorm normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 2 mg ml(‐1)